IDEAS home Printed from https://ideas.repec.org/r/eee/socmed/v21y1985i10p1063-1069.html
   My bibliography  Save this item

The demand for prescription drugs as a function of cost-sharing

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Paul Contoyannis & Jeremiah Hurley & Paul Grootendorst & Sung‐Hee Jeon & Robyn Tamblyn, 2005. "Estimating the price elasticity of expenditure for prescription drugs in the presence of non‐linear price schedules: an illustration from Quebec, Canada," Health Economics, John Wiley & Sons, Ltd., vol. 14(9), pages 909-923, September.
  2. Ii, Masako & Ohkusa, Yasushi, 2002. "Should the Coinsurance Rate Be Increased in the Case of the Common Cold? An Analysis Based on an Original Survey," Journal of the Japanese and International Economies, Elsevier, vol. 16(3), pages 353-371, September.
  3. Grossmann, Volker, 2013. "Do cost-sharing and entry deregulation curb pharmaceutical innovation?," Journal of Health Economics, Elsevier, vol. 32(5), pages 881-894.
  4. Annika Herr & Torben Stühmeier & Tobias Wenzel, 2023. "More cost‐sharing, less cost? Evidence on reference price drugs," Health Economics, John Wiley & Sons, Ltd., vol. 32(2), pages 413-435, February.
  5. Jouko Verho & Jarkko Harju, 2023. "Moral Hazard in Drug Purchases," Working Papers 12, Finnish Centre of Excellence in Tax Systems Research.
  6. Crown William H. & Berndt Ernst R. & Baser Onur & Finkelstein Stan N. & Witt Whitney P. & Maguire Jonathan & Haver Kenan E., 2004. "Benefit Plan Design and Prescription Drug Utilization Among Asthmatics: Do Patient Copayments Matter?," Forum for Health Economics & Policy, De Gruyter, vol. 7(1), pages 1-35, January.
  7. Alice Sanwald & Engelbert Theurl, 2017. "Out-of-pocket expenditures for pharmaceuticals: lessons from the Austrian household budget survey," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(4), pages 435-447, May.
  8. Danzon, Patricia M. & Chao, Li-Wei, 2000. "Cross-national price differences for pharmaceuticals: how large, and why?," Journal of Health Economics, Elsevier, vol. 19(2), pages 159-195, March.
  9. Granlund, David, 2008. "Does physicians' compensation affect the probability of their vetoing generic substitution?," Umeå Economic Studies 729, Umeå University, Department of Economics, revised 26 Mar 2008.
  10. Brekke, Kurt R. & Grasdal, Astrid L. & Holms, Tor Helge, 2009. "Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation?," European Economic Review, Elsevier, vol. 53(2), pages 170-185, February.
  11. Marin C. Gemmill & Joan Costa‐Font & Alistair McGuire, 2007. "In search of a corrected prescription drug Elasticity estimate: a meta‐regression approach," Health Economics, John Wiley & Sons, Ltd., vol. 16(6), pages 627-643, June.
  12. Abraham Jean M. & Royalty Anne Beeson & DeLeire Thomas, 2013. "Measuring the Financial Exposure from Medical Care Spending Among Families with Employer Sponsored Insurance," Forum for Health Economics & Policy, De Gruyter, vol. 16(1), pages 1-25, July.
  13. Alan, Sule & Crossley, Thomas F. & Grootendorst, Paul & Veall, Michael R., 2002. "The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada," Journal of Health Economics, Elsevier, vol. 21(5), pages 805-826, September.
  14. Yen, Steven T., 2003. "Estimating Demand For Cigarettes And Alcohol With Zero Observations:," 2003 Annual meeting, July 27-30, Montreal, Canada 22168, American Agricultural Economics Association (New Name 2008: Agricultural and Applied Economics Association).
  15. Piette, John D. & Heisler, Michele & Horne, Robert & Caleb Alexander, G., 2006. "A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures," Social Science & Medicine, Elsevier, vol. 62(4), pages 846-857, February.
  16. Li, M. & Ohkusa, Y., 2000. "An Empirical Research of Substitutability between Medical Services and Over-the-Counter Medication. An Analysis of Thirteen Different Minor Ailments," ISER Discussion Paper 0522, Institute of Social and Economic Research, Osaka University.
  17. Sule Alan & Thomas F. Crossley & Paul Grootendorst & Michael R. Veall, 2005. "Distributional effects of ‘general population’ prescription drug programs in Canada," Canadian Journal of Economics/Revue canadienne d'économique, John Wiley & Sons, vol. 38(1), pages 128-148, February.
  18. Kapur, Vishnu & Basu, Kisalaya, 2005. "Drug coverage in Canada: who is at risk?," Health Policy, Elsevier, vol. 71(2), pages 181-193, February.
  19. Granlund, David, 2009. "Are private physicians more likely to veto generic substitution of prescribed pharmaceuticals?," Social Science & Medicine, Elsevier, vol. 69(11), pages 1643-1650, December.
  20. Bakker, F. M. & van Vliet, R. C. J. A., 1995. "The introduction of deductibles for prescription drugs in a national health insurance: compulsory or voluntary?," Health Policy, Elsevier, vol. 31(1), pages 53-65, January.
  21. Doran, Evan & Robertson, Jane & Henry, David, 2005. "Moral hazard and prescription medicine use in Australia--the patient perspective," Social Science & Medicine, Elsevier, vol. 60(7), pages 1437-1443, April.
  22. Izhak, Olena, 2019. "Extra costs of integrity: Pharmacy markups and generic substitution in Finland," DICE Discussion Papers 307, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
  23. Lundberg, Lena & Johannesson, Magnus & Isacson, Dag G. L. & Borgquist, Lars, 1998. "Effects of user charges on the use of prescription medicines in different socio-economic groups," Health Policy, Elsevier, vol. 44(2), pages 123-134, May.
  24. Liu, Shuen-Zen & Romeis, James C., 2004. "Changes in drug utilization following the outpatient prescription drug cost-sharing program--evidence from Taiwan's elderly," Health Policy, Elsevier, vol. 68(3), pages 277-287, June.
  25. Arcidiacono, Peter & Ellickson, Paul B. & Landry, Peter & Ridley, David B., 2013. "Pharmaceutical followers," International Journal of Industrial Organization, Elsevier, vol. 31(5), pages 538-553.
  26. Paul V. Grootendorst & Mitchell Levine, 2002. "Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population," Social and Economic Dimensions of an Aging Population Research Papers 73, McMaster University.
  27. Dalen, Dag Morten & Sorisio, Enrico & Strøm, Steinar, 2009. "Choosing among Competing Blockbusters: Does the Identity of the Third-party Payer Matter for Prescribing Doctors?," Memorandum 10/2009, Oslo University, Department of Economics.
  28. Vincenzo Atella & Peter R. Noyce & Ellen Schafheutle & Karen Hassell, 2005. "Affordability of Medicines and Patients' Cost Reduction Behaviors: Empirical Evidence Based on SUR Estimates from Italy and the United Kingdom," CEIS Research Paper 71, Tor Vergata University, CEIS.
  29. David B. Ridley, 2015. "Payments, Promotion, And The Purple Pill," Health Economics, John Wiley & Sons, Ltd., vol. 24(1), pages 86-103, January.
  30. Carolin, Hoh & Ivonne, Honekamp, 2010. "Selbstbeteiligung als Lösung für das Moral-Hazard-Problem auf dem Arzneimittelmarkt? [Co-payment as a solution to the moral hazard problem in the pharmaceutical market?]," MPRA Paper 27425, University Library of Munich, Germany.
  31. Vincenzo Atella & Franco Peracchi & Domenico Depalo & Claudio Rossetti, 2006. "Drug compliance, co‐payment and health outcomes: evidence from a panel of Italian patients," Health Economics, John Wiley & Sons, Ltd., vol. 15(9), pages 875-892, September.
  32. Dalen Dag Morten & Locatelli Marilena & Sorisio Enrico & Strom Steinar, 2011. "A Probability Approach to Pharmaceutical Demand and Price Setting: Does the Identity of the Third-Party Payer Matters for Prescribing Doctors?," Department of Economics and Statistics Cognetti de Martiis. Working Papers 201110, University of Turin.
  33. Fiorio, Carlo V. & Siciliani, Luigi, 2010. "Co-payments and the demand for pharmaceuticals: Evidence from Italy," Economic Modelling, Elsevier, vol. 27(4), pages 835-841, July.
  34. Patricia Danzon;Li-Wei Chao, 2000. "Prices, Competition and Regulation in Pharmaceuticals: A Cross-National Comparison," Monograph 000462, Office of Health Economics.
  35. Noyce, Peter R. & Huttin, Christine & Atella, Vicenzo & Brenner, Gerhard & Haaijer-Ruskamp, Flora M. & Hedvall, Maj-Britt & Mechtler, Reli, 2000. "The cost of prescription medicines to patients," Health Policy, Elsevier, vol. 52(2), pages 129-145, June.
  36. Jan Zápal, 2010. "Doctor-Visit Co-Payment Exemption for Children: First Look at the Data," Czech Journal of Economics and Finance (Finance a uver), Charles University Prague, Faculty of Social Sciences, vol. 60(1), pages 58-72, February.
  37. Guido Citoni, 2015. "On the inverse relationship between ex-ante and ex-post moral hazard: the case of smokers," Working Papers CEB 15-041, ULB -- Universite Libre de Bruxelles.
  38. M. Fasihul Alam & David Cohen & Frank Dunstan & Dyfrig Hughes & Philip Routledge, 2018. "Impact of the phased abolition of co‐payments on the utilisation of selected prescription medicines in Wales," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 236-243, January.
  39. Fukushima, Kazuya & Mizuoka, Sou & Yamamoto, Shunsuke & Iizuka, Toshiaki, 2016. "Patient cost sharing and medical expenditures for the Elderly," Journal of Health Economics, Elsevier, vol. 45(C), pages 115-130.
  40. Andrew Street & Andrew Jones & Aya Furuta, 1997. "Cost-sharing and pharmaceutical utilisation in Russia: evidence from a household survey," Working Papers 155chedp, Centre for Health Economics, University of York.
  41. Lagarde, Mylène & Blaauw, Duane, 2022. "Overtreatment and benevolent provider moral hazard: Evidence from South African doctors," Journal of Development Economics, Elsevier, vol. 158(C).
  42. Lagarde, Mylène & Blaauw, Duane, 2022. "Overtreatment and benevolent provider moral hazard: evidence from South African doctors," LSE Research Online Documents on Economics 115383, London School of Economics and Political Science, LSE Library.
  43. Cecilia S. Diaz-Campo, M. Antonella Mancino, 2023. "What We RANDomly Did Not Learn: Opioid Elasticities and Underlying Mechanisms," LCERPA Working Papers bm0139, Laurier Centre for Economic Research and Policy Analysis.
  44. Granlund, David, 2012. "The effect of pharmacies’ right to negotiate discounts on the market share of parallel imported pharmaceuticals," HUI Working Papers 75, HUI Research.
  45. Atella, Vincenzo, 2000. "Drug cost containment policies in Italy: are they really effective in the long-run?: The case of minimum reference price," Health Policy, Elsevier, vol. 50(3), pages 197-218, January.
  46. Haiden A. Huskamp & Richard G. Frank & Kimberly A. McGuigan & Yuting Zhang, 2005. "The Impact of a Three‐Tier Formulary on Demand Response for Prescription Drugs," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 14(3), pages 729-753, September.
  47. Crea, Giovanni & Galizzi, Matteo M. & Linnosmaa, Ismo & Miraldo, Marisa, 2019. "Physician altruism and moral hazard: (no) Evidence from Finnish national prescriptions data," Journal of Health Economics, Elsevier, vol. 65(C), pages 153-169.
  48. Jaume Puig‐Junoy & Pilar García‐Gómez & David Casado‐Marín, 2016. "Free Medicines Thanks to Retirement: Impact of Coinsurance Exemption on Pharmaceutical Expenditures and Hospitalization Offsets in a national health service," Health Economics, John Wiley & Sons, Ltd., vol. 25(6), pages 750-767, June.
  49. Sabrina Terrizzi & Chad Meyerhoefer, 2020. "Estimates Of The Price Elasticity Of Switching Between Branded And Generic Drugs," Contemporary Economic Policy, Western Economic Association International, vol. 38(1), pages 94-108, January.
  50. Sherry Glied & Tama Brooks, 1997. "The Market and the Estimators: Forecasting the Cost of Medicare Catastrophic Coverage," NBER Working Papers 6287, National Bureau of Economic Research, Inc.
  51. Alice Sanwald & Engelbert Theurl, 2014. "Out-of-pocket expenditures of private households for dental services - Empirical evidence from Austria," Working Papers 2014-30, Faculty of Economics and Statistics, Universität Innsbruck.
  52. Sarma, Sisira & Basu, Kisalaya & Gupta, Anil, 2007. "The influence of prescription drug insurance on psychotropic and non-psychotropic drug utilization in Canada," Social Science & Medicine, Elsevier, vol. 65(12), pages 2553-2565, December.
  53. Street, Andrew & Jones, Andrew & Furuta, Aya, 1999. "Cost-sharing and pharmaceutical utilisation and expenditure in Russia," Journal of Health Economics, Elsevier, vol. 18(4), pages 459-472, August.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.